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Abstract
Background: Aberrant mutations in KRAS play a critical role in tumor initiation and progression, and are a negative
prognosis factor in lung adenocarcinoma (LUAD).
Results: Using genomic analysis for K-Ras isoforms (K-Ras4A and K-Ras4B) and large-scale multi-omics data, we inspected
the overall survival (OS) and disease-free survival (DFS) of LUAD patients based on the abundance of transcript variants by
analyzing RNA expression and somatic mutation data from The Cancer Genome Atlas (n = 516). The expression of the
minor transcript K-Ras4A and its proportion were positively correlated with the presence of KRAS mutations in LUAD.
We found that both K-Ras4A abundance measures (expression and proportion) have a strong association with poor OS
(p = 0.0149 and p = 3.18E-3, respectively) and DFS (p = 3.03E-4 and p = 0.0237, respectively), but only in patients harboring
KRAS mutations. A Cox regression analysis showed significant results in groups with low expression (hazard ratio (HR) = 2.
533, 95% confidence interval (CI) = 1.380−4.651, p = 2.72E-3) and low proportion (HR = 2.549, 95% CI = 1.387−4.684, p = 2.
58E-3) of K-Ras4A.
Conclusions: Based on the above results, we report the possible use of abundance measures for K-Ras4A for predicting
the survival of LUAD patients with KRAS mutations.
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Background
KRAS mutations are present in approximately 30% of
cases of lung cancer [1–4], in which amino acid alter-
ations from Gly12 to Ala, Cys, Asp, and Val are most
frequently detected. Aberrantly mutated KRAS has been
shown to play a critical role in cancer initiation and
maintenance by modulating oncogenic downstream ef-
fectors including Raf and PI3K, followed by the Raf/
MEK/ERK and the PI3K/Akt pathways, respectively [5].
KRAS has also been shown to be a negative prognostic
marker for lung cancer [3]. Mutual exclusiveness be-
tween KRAS and EGFR mutations [6] led to the three
classifications of lung cancer groups: KRAS mutants,
EGFR mutants, and KRAS/EGFR wild type [7]. However,
no further stratifications have been available for lung
cancer patients and KRAS mutations [7, 8]. Considering
the prevalence of mutations in lung cancer and subse-
quent heterogeneous outcomes [2], we hypothesize that
there are additional prognosis markers for patients with
KRAS mutations, which may be possibly based on un-
seen traits of the gene.
KRAS amplification has been known to be frequently
occurred in non-small cell lung cancer (NSCLC) [9, 10],
of which the prevalence was reported to approximately
15%, revealing one of the common molecular alterations
in NSCLC. Copy number gain of the gene has also been
known to lead poor clinical outcome in NSCLC patients
[11]. In addition, increased copy number of a gene
may be closely related to its allelic imbalance. Indeed,
a recent study revealed that KRAS showed imbalanced* Correspondence: swkim@yuhs.ac
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allelic expression in TCGA LUAD cancer type by compar-
ing variant allele frequencies between DNA and RNA [12].
KRAS produces two splice variants (K-Ras4A and K-
Ras4B) by alternative splicing, which are differentiated by
alternative use of the last two exons [1]. Because the ma-
jority of KRAS mutations occur in the shared exon 2 (12th
and 13th codons) and 3 (61st codon), both K-Ras4A and
K-Ras4B isoforms are oncogenic. The isoforms also differ
by the hypervariable region (HVR) sequences, where K-
Ras4B contains a long polybasic stretch, while K-Ras4A
has a short polybasic region with a palmitoylation site. As
a result of their distinct genetic structures, their biological
characteristics, such as plasma membrane binding, have
been shown to be different [1, 13]. Generally, K-
Ras4B has been shown to be the predominant form.
However, frequent co-expression of the two isoforms
has been found in multiple cancer types in a recent
study [13]. Taken together, the expression pattern of
the K-Ras isoforms can affect the cellular mechanisms
of lung cancer, which may further influence the prog-
nosis of the patients. Furthermore, a recent publica-
tion reported that K-Ras4A showed some structurally
different characteristics compared to K-Ras4B as fol-
lowing: i) a more exposed nucleotide binding pocket
in GDP-bound form; ii) different dynamic fluctuations
in switch I and II regions; and iii) unstable autoinhib-
ited state of HVR [14]. These results might imply
some different roles in regulation of KRAS signaling
between both K-Ras isoforms.
In light of high throughput transcriptome sequencing
technology, such as RNA-seq [15] and related bioinfor-
matics algorithms [16, 17], the traditional analysis of
mRNA expression levels expression has been extended to
the accurate quantification and structural determination
of transcript variants. In addition, the availability of multi-
omics cancer data from a large cohort, such as The
Cancer Genome Atlas (TCGA) project [18], and conveni-
ent web platforms as demonstrated in our previous work
[19], have enabled instant genome-level analyses. Inspec-
tion of the isoform-level traits of a gene provides deeper
and more detailed insights to understand the biological
characteristics of human cancers compared to previous
gene-level analysis.
Here, we report the possible use of the expression pat-
tern of K-Ras isoforms in the prediction of lung cancer sur-
vival, demonstrated by the statistical analysis of RNA-seq
data from 516 patients with lung cancer adenocarcinoma
(LUAD). We found that the abundance measurements
(expression and proportion) for the K-Ras4A isoform are
strongly associated with the presence of KRAS mutations
as well as a positive prognosis for lung cancer patients
harboring KRAS mutations. Multivariate analysis identi-
fied that the two measures of the isoform can be inde-
pendent predictors.
Methods
Data acquisition and processing
We downloaded somatic mutation data files (level 2)
and RNA sequencing (RNA-seq) data sets (level 3, RNA-
seq v2 expression data) for LUAD from the TCGA Data
Portal, which are currently stored in the Genomic Data
Commons Legacy Archive [20] that is maintained by the
National Cancer Institute (Additional file 1: Table S1).
For RNA-seq data sets, 516 tumor samples annotated
as “primary solid tumor” were only included in this
study. Transcripts per million (TPM) was used as a unit
representing expression levels of genes and isoforms,
which were calculated by multiplying the estimated frac-
tion of transcripts made up by a given isoform or gene
ranging from zero to one computed using RSEM [21].
An average TPM value was used if two or more expres-
sion levels of the gene or isoform were found for the
same patient. A threshold of TPM > 10− 6 was applied to
determine whether the gene or isoform was expressed or
not as used in previous study [19]. Isoform proportions
of a gene were calculated by dividing the TPM value of
each isoform by the sum of TPM values of all isoforms.
Clinical information (Merge_Clinical, version 2016_01_28)
for the LUAD patients was obtained from FireBrowse
[22], which is maintained by the Broad Institute. The
following metrics were extracted for comparisons of
clinic-pathological characteristics, survival analysis, and
Cox regression analysis: age, gender, smoking history,
pathological stage, days to death, days to last follow-up,
days to new tumor event after initial treatment, and vital
status. Copy number alteration data (CopyNumber Gis-
tic2, level4, version 2016_01_28) was also obtained from
the FireBrowse [22], where the samples with KRAS ampli-
fication were determined with the threshold of 10%.
For comparison with the analysis results from LUAD,
we also downloaded the same data sets and then pre-
pared them as described above for the three cancer types
(colon adenocarcinoma, COAD; pancreatic adenocarcin-
oma, PAAD; and rectal adenocarcinoma; READ) as shown
in Additional file 1: Table S2.
Identification of associations between the isoform and
mutation state of KRAS
KRAS is one of the most frequently mutated genes in
the LUAD cancer type [23]. Thus, the gene was targeted
to examine for associations between the isoform and
mutation state. After binning patient samples according
to their orders sorted by expression levels or proportions
for individual isoforms of the gene in each cancer type, a
linear regression analysis was performed to calculate the
R-squared (r2) and slope (S) with average expression level
or proportion of each corresponding isoform and sum of
the patients with KRAS mutations in each bin. If skewing
of the line was found in the analysis, we recalculated r2
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and S values after excluding outliers. We determined the
presence or absence of an association with the r2 and S
threshold of 0.6.
Patient grouping
Patients of each cancer type were divided into high and
low groups based on median values for expression levels
or proportions of respective K-Ras isoforms (K-Ras4A
and K-Ras4B) as shown in Additional file 1: Table S3.
Each group was further divided into two subgroups ac-
cording to the presence or absence of KRAS mutations,
thus generating four groups for each K-Ras isoform. For
intuitive notation of these groups, we designated high
and low expression groups of the K-Ras4A isoform to
KAexphigh and KAexplow, respectively, and denoted high
and low proportion groups of the isoform to KAprophigh
and KAproplow, respectively. In addition, we examined the
mutation states (present or absent) of EGFR (G719A/C/S,
exon 19 deletions, exon 20 insertions, S768I, T790 M,
L858R, and L861Q), and KRAS (mutations at the 12th,
13th, and 61st codons) for all patients. We then denoted
patient groups harboring mutant and wild type (wt) of
KRAS and EGFR genes to KRASmut and KRASwt; and
EGFRmut and EGFRwt, respectively. Patient group with or
without KRAS amplification was designated to KRASamp(+)
and KRASamp(−). Note that KRASamp(−) group includes pa-
tients with not only neutral but also decreased copy num-
ber of the gene.
Statistical analysis
Overall survival (OS) and disease-free survival (DFS) rates
were analyzed using the Kaplan-Meier method, and a log-
rank test was used to compare the high and low groups.
Cox regression analysis was performed with nine variables
(age, gender, smoking history, K-Ras4A expression, K-
Ras4A proportion, KRAS amplification, KRAS mutation,
EGFR mutation, and pathological stage) to test for
independent markers of OS. Age, gender, smoking history,
and pathological stage were entered into the Cox propor-
tional hazard model as class variables. The relationship
between nominal variables was examined by Chi-square
tests. The limit of significance for all analyses was defined
with a p value of 0.05. Analyses were performed by using
the statistical software R version 3.3.2.
Results
Expression levels and proportions of K-Ras isoforms
The distributions for expression levels (A) and propor-
tions (B) of the two K-Ras isoforms for the LUAD cancer
types are shown in Fig. 1, where the K-Ras4B isoform
was observed as a major type as reported in a previous
study [13]. Similar patterns were also observed for other
cancer types (COAD, PAAD, and READ; Additional file
2: Figure S1). KRAS mutations and amplification are rep-
resented with red and blue bars, respectively, on the top
of each panel in these figures. For KRAS mutations, we
observed some trends with expression levels or propor-
tions of a K-Ras isoform. For example, expression of the
K-Ras4B isoform was increased according to increasing
incidence rates of KRAS mutations in LUAD and READ
(Fig. 1a and Additional file 2: Figure S1E, respectively).
The proportions of the K-Ras4B isoform decreased ac-
cording to increasing incidence rates of KRAS mutations
in LUAD, but opposite was observed for the proportion
of K-Ras4A (Fig. 1b). When we also checked for KRAS
amplification, K-Ras4B expression seemed to have corre-
lations with KRAS amplification in each cancer type un-
likely proportions of both K-Ras isoforms (Fig. 1 and
Additional file 2: Figure S1).
Association between K-Ras isoforms and KRAS mutations
Next, we investigated how the degree of association be-
tween the K-Ras isoforms and KRAS mutations appeared
in each cancer type via r2 and S values obtained from
Fig. 1 Isoform-level analyses of KRAS using the LUAD data set. Distribution of expression levels (a) and proportions (b) of K-Ras4A and K-Ras4B isoforms
for LUAD patient samples, where KRAS mutations and amplification are represented to red and blue bars on the top of each panel
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a linear regression analysis (Fig. 2a−c for LUAD and
Additional file 2: Figure S2 for COAD, PAAD, and READ).
When we examined for an association between K-Ras4A
expression levels and the mutations, the LUAD and READ
cancer types had r2 values (0.940 and 0.765, respectively)
greater than the threshold of 0.6, of which only the S value
for LUAD exceeded the threshold (2.748). For K-Ras4B
expression levels versus the mutations, the r2 value for
LUAD and READ (0.738 and 0.841, respectively) exceeded
the threshold, but only S value for LUAD was greater than
0.6 (0.693). When we examined for the relationship be-
tween proportions of the two K-Ras isoforms and KRAS
mutations, we selected the K-Ras4A instead of K-Ras4B
isoform since K-Ras4A exhibited a positive association
(positive S value), whereas the r2 values between the two
isoforms were the same. While all cancer types had S
values that exceeded the threshold, only the r2 value for
LUAD was higher than the threshold (0.903). The above
results revealed that the LUAD cancer type had a clear
and strong association of not only expression levels, but
also proportions of the K-Ras4A isoform with KRAS
mutations.
Association between K-Ras isoforms and KRAS
amplification
We also examined association between isoforms and amp-
lification of the gene via linear regression analysis in each
cancer type (Fig. 2d−f for LUAD and Additional file 2:
Figure S3 for COAD, PAAD, and READ). For K-Ras4A
expression, LUAD showed strong association with KRAS
amplification (S = 0.781, r2 = 0.945), but no or weak cor-
relation was observed in other cancer types. For K-Ras4B
expression, all cancer types exhibited more than moderate
association (r2 > 0.6), of which the highest value was ap-
peared in LUAD (r2 = 0.945). However, no correlation was
found between K-Ras4A proportion and KRAS amplifica-
tion (r2 < 0.2). Taken together, only KRAS amplification of
LUAD cancer type showed strong association with expres-
sion of both K-Ras isoforms (r2 > 0.9), although S value
was less than 0.6 for K-Ras4B expression.
Correlation of K-Ras4A isoform with Clinicopathological
parameters
We examined whether the K-Ras4A expression levels or
proportions were associated with the clinicopathological
parameters of LUAD patients as shown in Table 1. Both
K-Ras4A expression levels and proportions were signifi-
cantly associated with mutation states of KRAS (p = 4.82E-
12 and p = 2.49E-07, respectively) and EGFR (p = 1.81E-3
and p = 0.0125, respectively) as well as the pathological
stage (p = 0.0460 and p = 0.0327, respectively). Unlike
KRAS mutation states, KRAS amplification was associated
with K-Ras4A expression (p = 2.70E-3), but not for K-
Ras4A proportion (p = 1.0). No association was ob-
served with age (p = 1.0 and p = 0.616, respectively),
gender (p = 1.0 and p = 0.791, respectively), and smoking
history (p = 0.299 and p = 1.0, respectively). We confirmed
that both K-Ras4A expression levels and proportions were
correlated to the mutation states of well-known oncogenes
(KRAS and EGFR) along with the pathological stages and
Fig. 2 Linear regression analyses. The first (a, b, and c) and second rows (d, e, and f) indicate the results for KRAS mutations and amplification,
respectively. The first (a and d), second (b and e), and third columns (c and f) represent the results for K-Ras4A expression, K-Ras4B expression,
and K-Ras4A proportion, respectively. S and r2 indicate slope and R-squared, respectively
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only K-Ras4A expression levels were related to KRAS amp-
lification. In addition, we found more significant p values
in K-Ras4A expression than those in K-Ras4A proportion
as following: 2.70E-3 versus 1.0 for KRAS amplification,
4.82E-12 versus 2.49E-7 for KRAS mutations, and 1.83E-3
versus 0.0125 for EGFR mutations, which seemed to sug-
gest that K-Ras4A expression was stronger factor than K-
Ras4A proportion.
OS according to KRAS mutation states
We examined the OS of LUAD patients according to the
presence or absence of KRAS mutations, and confirmed
that there were no significant differences in OS between
the KRASmut and KRASwt groups (p = 0.227, Fig. 3a). We
knew that patients with pathological stage I occupied
more than 50% (276/516 [53.5%], Table 1). When we re-
analyzed their OS with respect to pathological stages (I,
II, or III/IV), no significant differences according to the
mutation states were observed in patients with patho-
logical stage I (p = 0.312, Additional file 2: Figure S4A).
Accordingly, we assumed that the biased inclusion of
the patients with pathological stage I might result in un-
distinguishable OS results according to the KRAS
mutation states of all LUAD patients. By contrast, in
cases of two patient groups with pathological stage II or
III/IV, respectively, patients with KRAS mutations had
relatively poor OS compared to patients with wild type
KRAS although these results were not statistically signifi-
cant (p = 0.145 for stage II, Additional file 2: Figure S4B;
p = 0.153 for stage III/IV, Additional file 2: Figure S4C).
OS according to KRAS amplification
We investigated OS according to the presence or ab-
sence of KRAS amplification for all LUAD patients.
Significant poor outcome was observed in KRASamp(+)
group compared to KRASamp(−) group (p = 9.50E-3,
Fig. 3b). Sasaki et al. reported that KRAS mutation
plus increased copy number was a predictor of poor
clinical outcome in patients with NSCLC [11]. Accordingly,
we examined their OS after dividing LUAD patient into
three groups (KRASwt/KRASamp(−), KRASmut/KRASamp(+),
and the remained patients). KRASmut/KRASamp(+) group
showed the worst prognosis among them, although
the result was not statistically significant (p = 0.0872,
Additional file 2: Figure S5).
Table 1 Baseline data of LUAD patients according to the expression and proportion of the K-Ras4A isoform
Clinical parameters Values All patients K-Ras4A expressiona K-Ras4A proportionb
N (%) High [N (%)] Low [N (%)] p-valuec High [N (%)] Low [N (%)] p-value
Age ≥65 276 (53.5) 137 (26.6) 139 (26.9) 1.0 141 (27.3) 135 (26.2) 0.616
< 65 221 (42.8) 110 (21.3) 111 (21.5) 107 (20.7) 114 (22.1)
NAd 19 (3.7) 11 (2.1) 8 (1.6) 10 (1.9) 9 (1.9)
Gender Male 238 (46.1) 119 (23.1) 119 (23.1) 1.0 117 (22.7) 121 (23.4) 0.791
Female 278 (53.9) 139 (26.9) 139 (26.9) 141 (27.3) 137 (26.6)
Smoking history Yes 427 (82.8) 219 (42.4) 208 (40.3) 0.299 215 (41.7) 212 (41.1) 1.0
No 75 (14.5) 33 (6.4) 42 (8.1) 38 (7.4) 37 (7.2)
NA 14 (2.7) 6 (1.2) 8 (1.6) 5 (1.0) 9 (1.7)
KRAS amplificatione Present 61 (11.8) 42 (8.1) 19 (3.7) 2.70E-3 30 (5.8) 31 (6.0) 1.0
Absent 455 (88.2) 216 (41.9) 239 (46.3) 228 (44.2) 227 (44.0)
KRAS mutations Present 148 (28.7) 110 (21.3) 38 (7.4) 4.82E-12 101 (19.6) 47 (9.1) 2.49E-7
Absent 368 (71.3) 148 (28.7) 220 (42.6) 157 (30.4) 211 (40.9)
EGFR mutations Present 45 (8.7) 12 (2.3) 33 (6.4) 1.81E-3 14 (2.7) 31 (6.0) 0.0125
Absent 471 (91.3) 246 (47.7) 225 (43.6) 244 (47.3) 227 (44.0)
Pathological stage I 276 (53.5) 125 (24.2) 151 (29.3) 0.0460 128 (24.8) 148 (28.7) 0.0327
II 122 (23.6) 66 (12.8) 56 (10.9) 58 (11.2) 64 (12.4)
III 84 (16.3) 52 (10.1) 32 (6.2) 54 (10.5) 30 (5.8)
IV 26 (5.0) 13 (2.5) 13 (2.5) 14 (2.7) 12 (2.3)
NA 8 (1.6) 2 (0.4) 6 (1.2) 4 (0.8) 4 (0.8)
aMedian value (3.41 TPM) of K-Ras4A expression levels was used to divide LUAD patients into two groups
bMedian value (0.1659) of K-Ras4A proportions was used to divide LUAD patients into two groups
cChi square tests were used to examine the relationship between the nominal variables
dNA, Not available
eThe presence or absence of KRAS amplification were defined to 10% or more KRAS amplified or not
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OS according to K-Ras4A isoform expression and
proportion
The Kaplan-Meier curves for the LUAD patients accord-
ing to the expression levels or proportions of the K-
Ras4A isoform are shown in Fig. 4. For all patients, there
were no significant differences in OS between the two
groups (p = 0.0698 for KAexphigh versus KAexplow, Fig.
4a; p = 0.735 for KAprophigh versus KAproplow, Fig. 4d).
Since KRAS is a well-known oncogenic driver in lung
cancer [3, 7], we further compared OS according to the
mutational states of the gene in each group. In the
KRASmut group, both KAexplow and KAproplow subgroups
showed significantly worse OS than the KAexphigh and
KAprophigh subgroups (p = 0.0149 and p = 3.18E-3, re-
spectively; Fig. 4b, e). By checking the DFS, we confirmed
that the OS results were convincing for the K-Ras4A ex-
pression (p = 3.03E-3, Additional file 2: Figure S6B) and
proportion groups (p = 0.0237, Additional file 2: Figure
S6E) for LUAD patients with KRAS mutations but not
for all patients. Since KRAS amplification has been
also identified as poor prognosis factor [11], OS of
KRASamp(+) group was also examined and then com-
pared with the results of KRASmut group. However,
we did not observe significant OS results according
to the high and low groups of K-Ras4A expression
and proportion in the group (p = 0.145 and p = 0.315,
Fig. 4 Overall survival of LUAD patients according to K-Ras4A expression and proportion. The first (a, b, and c) and second rows (d, e, and f)
indicate the curves for the KAexphigh versus KAexplow groups and KAprophigh versus KAproplow groups, respectively. The first (a and d), second
(b and e), and third columns (c and f) represent the curves for all patients, patients with KRAS mutations (KRASmut group), and patients with KRAS
amplification (KRASamp(+) group), respectively. X- and y-axes represent survival time (days) and survival ratio, respectively
Fig. 3 Overall survival of LUAD patients according to the states of KRAS mutations (a) and amplification (b). X- and y-axes represent survival time
(days) and survival ratio, respectively
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respectively; Fig. 4c, f). This antagonistic result might be
expected from the fact that only 27 LUAD patients simul-
taneously harbored both KRAS mutations and amplifica-
tion. From these results, we questioned how were the
LUAD patients with KRAS mutations divided into the two
groups showing good and poor OS results according to K-
Ras4A expression or proportion. Accordingly, we further
examined the patient groups showing poor survival.
Cox regression analysis
Using the Cox proportional hazards model, we investi-
gated the hazard ratio (HR) of K-Ras4A expression and
proportion in the LUAD cancer type. Table 2 shows the
HRs and the significances of several covariates including
K-Ras4A expression (A) or proportion (B) from uni- and
multivariate analyses for all LUAD patients. The highest
HR values were found in the subgroups for patients with
pathological stage III/IV (HR = 2.486, 95% confidence
interval [CI] = 1.796−3.443, and p = 4.14E-8 for expression
groups; HR = 2.513, 95% CI = 1.815−3.480, and p = 2.90E-
8 for proportion groups). For EGFR and KRAS mutations,
HR values ranged from 1.246 to 1.460, which were not ob-
served to be significant in both results. Under the same
condition, we detected not only neutral HR values for K-
Ras4A expression and proportion (0.900 and 1.049, re-
spectively) but also a lack of their significances (0.537 and
0.770, respectively). These results were coincident with no
significant OS and DFS differences between high and low
groups for all LUAD patients (Fig. 4a, d and Additional file
2: Figure S6A, D). In contrast to mutation states of EGFR
and KRAS, absence of KRAS amplification in all LUAD
patients showed significant results when tested with K-
Ras4A expression (HR = 0.623, 95% CI = 0.395−0.983, and
p = 0.0421) and proportion (HR = 0.619, 95% CI = 0.393
−0.977, and p = 0.0939), which were coincident with OS
result as shown in Fig. 3b. Furthermore, results from the
uni- and multivariate analyses for the patients with KRAS
mutations (KRASmut) are shown in Table 3. Pathological
stage III/IV was also detected as a significant and inde-
pendent factor with the highest HR value (HR = 3.268,
95% CI = 1.793−5.954, and p = 1.10E-4 for expression
groups; HR = 3.404, 95% CI = 1.867−6.207, and p = 6.41E-
5 for proportion groups). For KRAS amplification, non-
significant p values (0.558 for expression groups and 0.903
for proportion groups) were observed unlikely the results
from all LUAD patients, which were consisted with the re-
sults from survival analysis (Fig. 4c, f). In the same condi-
tion, both K-Ras4A expression and proportion had HR
values greater than 2 (2.533 and 2.549, respectively) and
appeared to be significant (2.72E-3 and 2.58E-3, respect-
ively), thereby representing that they were equivalent
independent markers for LUAD patients with KRAS mu-
tations. Furthermore, these results were consistent with
OS (Fig. 4b, e) and DFS results (Additional file 2: Figure
S6B, E) for the corresponding patients. Finally, we exam-
ined the significance of the multivariate analysis for the
intersect set of the two low groups showing poor survival
by testing the following four groups: KAexphigh/KApro-
phigh (n = 96); KAexphigh/KAproplow (n = 14); KAexplow/
KAprophigh (n = 5); and KAexplow/KAproplow (n = 33;
Additional file 1: Table S4). As expected, the most
significant group was identified to be KAexplow/KAproplow
Table 2 Cox regression analysis for all LUAD patients
Covariates A. K-Ras4A expression Covariates B. K-Ras4A proportion
Univariate analysis Multivariate analysis Univariate analysis Multivariate analysis
HRa
(95% CIb)
p-value HR
(95% CI)
p-value HR
(95% CI)
p-value HR
(95% CI)
p-value
Age (≥65 years) 1.154
(0.857−1.553)
0.346 1.198
(0.879−1.632)
0.253 Age (≥65 years) 1.154
(0.857−1.553)
0.346 1.206
(0.885−1.643)
0.236
Gender (Male) 1.063
(0.797−1.417)
0.678 1.190
(0.871−1.625)
0.274 Gender (Male) 1.063
(0.797−1.417)
0.678 1.185
(0.867−1.619)
0.287
Smoking history 1.019
(0.887−1.170)
0.790 1.038
(0.895−1.202)
0.625 Smoking history 1.019
(0.887−1.170)
0.790 1.039
(0.896−1.204)
0.615
K-Ras4A expression
(low)
0.766
(0.573−1.023)
0.0705 0.900
(0.644−1.257)
0.537 K-Ras4A proportion
(low)
0.952
(0.714−1.268)
0.735 1.049
(0.762−1.444)
0.770
KRAS amplification
(Not amplified)
0.580
(0.382−0.880)
0.0104 0.623
(0.395−0.983)
0.0421 KRAS amplification
(Not amplified)
0.580
(0.382−0.880)
0.0104 0.619
(0.393−0.977)
0.0393
KRAS mutations
(Present)
1.194
(0.867−1.643)
0.277 1.246
(0.856−1.813)
0.252 KRAS mutations
(Present)
1.194
(0.867−1.643)
0.277 1.319
(0.915−1.901)
0.138
EGFR mutations
(Present)
1.322
(0.831−2.104)
0.239 1.460
(0.869−2.454)
0.153 EGFR mutations
(Present)
1.322
(0.831−2.104)
0.239 1.436
(0.855−2.412)
0.172
Pathological
stage (III/IV)
2.635
(1.939−3.581)
5.94E-10 2.486
(1.796−3.443)
4.14E-8 Pathological stage
(III/IV)
2.635
(1.939−3.581)
5.94E-10 2.513
(1.815−3.480)
2.90E-8
aHR, hazard ratio
bCI, confidence interval
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(HR = 2.816, 95% CI = 1.453−5.459, and p = 2.17E-3), of
which the statistical significance was similar to the above
individual test results for K-Ras4A expression and propor-
tion. Taken together, we suggest the possibility of both K-
Ras4A expression and proportion to be utilized in survival
predictions for LUAD patients with KRAS mutations. Note
that one of the two factors should be used for the purpose,
since moderate relationship (Pearson coefficient [r] = 0.505)
was observed between K-Ras4A expression levels and
proportions.
Discussion
The advents of RNA-seq technology and relevant bioinfor-
matics tools have enabled us to perform isoform-level ex-
pression analyses via reliable identification of the isoforms.
The approach has been used for various kinds of cancer re-
search including the detection of tumor-specific isoforms
[24], thereby enabling the identification of potential bio-
markers for clinical purposes including diagnosis [24, 25].
In this study, we presented another utility of isoform-level
analysis that enabled a possible predictive role of abundance
measures for the K-Ras4A isoform on the survival of LUAD
patients harboring KRASmutations. In light of the statistical
significance, we anticipate that isoform-level abundance of
genes may confer a new factor for a deeper consideration of
patient prognosis and stratification in cancer.
A recent study reported that KRAS was one of the
genes showing significantly positive variant allele fre-
quencies in RNA compared to DNA [12]. Accordingly, it
was needed to check whether each K-Ras isoform was
expressed from mutant or wild type alleles in the condi-
tion of allelic imbalance of KRAS transcription. Current
paired-end sequencing technology makes it possible to
achieve the purpose by examining read pairs. But direct
investigation in the cancer type was impossible due to
the absence of raw RNA-seq data. Instead, we examined
the corresponding read pairs in other lung adenocarcin-
oma data set generated by paired-end sequencing
(GSE81089 [26]). Because relatively long fragment sizes
are required for KRAS mutations at 12th or 13th codons
than that at 61st codon, we could observe one or two read
pairs in the former cases, while several read pairs were
found in the latter case (Additional file 2: Figure S7). Since
this examination is depend on the degree of fragmentation
before sequencing, excessive fragmentation of template
RNA molecules during library preparation will be compli-
cated to confirm both KRAS mutation status and isoform
origin of the read pairs. Indeed, we could not find them
due to the lack of fragments satisfying the minimal size in
another lung adenocarcinoma data set (GSE40419 [27];
data not shown).
While our analysis has been conducted based on a ro-
bust measurement of gene expression in a sufficiently
large-scale cohort, there are some intrinsic limitations
that may affect the interpretation and the reproducibility
of the study. Generally, the causal relation between the
molecular factor (here, K-Ras expression) and the sur-
vival (OS) can be hardly drawn in cohort-based studies,
which can weaken the functional association. Moreover,
the use and the definition of OS can be different by the
study design. For example, there are four distinct uses of
OS as a metric: i) survival time as a patient outcome, ii)
patient survival as a therapeutic objective, iii) OS as a
trial endpoint, and iv) survival as a public health meas-
ure [28]. The OS of patients who participated in the
TCGA project [18] might have been used as a therapeutic
metric by clinicians to track their survival. Accordingly,
the OS used in this study could be affected by several fac-
tors including pathological states and individual responses
for chemo- and/or targeted therapies. Further studies are
Table 3 Cox regression analysis for LUAD patients harboring KRAS mutations
Covariates A. K-Ras4A expression Covariates B. K-Ras4A proportion
Univariate analysis Multivariate analysis Univariate analysis Multivariate analysis
HRa
(95% CIb)
p-value HR
(95% CI)
p-value HR
(95% CI)
p-value HR
(95% CI)
p-value
Age (≥65 years) 1.326
(0.761−2.312)
0.320 1.351
(0.735−2.480)
0.333 Age (≥65 years) 1.326
(0.761−2.312)
0.320 1.443
(0.778−2.678)
0.245
Gender (Male) 1.536
(0.891−2.650)
0.123 1.734
(0.954−3.152)
0.0711 Gender (Male) 1.536
(0.891−2.650)
0.123 1.690
(0.911−3.061)
0.0971
Smoking history 1.076
(0.804−1.440)
0.622 1.168
(0.851−1.602)
0.337 Smoking history 1.076
(0.804−1.440)
0.622 1.191
(0.866−1.638)
0.282
KRAS amplification
(Not amplified)
0.820
(0.410−1.643)
0.576 0.802
(0.383−1.679)
0.558 KRAS amplification
(Not amplified)
0.820
(0.410−1.643)
0.576 0.954
(0.448−2.031)
0.903
K-Ras4A expression
(low)
1.986
(1.131−3.490)
0.017 2.533
(1.380−4.651)
2.72E-3 K-Ras4A proportion
(low)
2.258
(1.295−3.938)
4.10E-3 2.549
(1.387−4.684)
2.58E-3
Pathological stage
(III/IV)
3.088
(1.747−5.459)
1.05E-4 3.268
(1.793−5.954)
1.10E-4 Pathological stage
(III/IV)
3.088
(1.747−5.459)
1.05E-4 3.404
(1.867−6.207)
6.41E-5
aHR, hazard ratio
bCI, confidence interval
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also needed to confirm whether our findings are also ob-
served in other lung cancer data sets before being applied
in clinical practice. Finally, the lack of proper independent
cohort for validation is a remaining hurdle. As known,
TCGA is the currently largest cohort that provides multi-
omics data with well-defined clinical information. Based
on an extensive search, we found one and the only avail-
able independent cohort with raw RNA-seq data and sur-
vival information (GSE81089 [26]). However, application
of our analysis on the cohort was unsuccessful, due to the
smaller cohort size (n = 108, compared to 516 in TCGA)
and low sample purity criteria (> 10%, compared to > 50%
in TCGA). We would like to note that the purity of sam-
ple is extremely important to measuring gene expression
of cancer cells, because inclusion of normal cells (e.g.,
stromal cells) can perplex the inference of cancer specific
mRNA abundance. We anticipate that the completion and
the public distribution of currently ongoing large-scale
genomic projects such as International Cancer Genome
Consortium [29] and Genomics Evidence Neoplasia
Information Exchange [30] will lead to a proper evaluation
of the association between isoform expression and cancer
prognosis.
Conclusions
By performing an isoform-level analysis, we found two
abundance measures (expression and proportion) for the
K-Ras4A isoform that were associated with survival rate of
patients with both LUAD and KRAS mutations. We
showed their possibility in predicting lung cancer survival
rates by identifying their roles as independent prognostic
markers through multivariate analysis. Furthermore, we
demonstrated that isoform-level analysis was a very useful
approach in identifying hidden factors that can be utilized
in the clinic.
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